Business Context and Reporting Period
This Form 8-K Current Report was filed by REGENXBIO Inc. on June 29, 2020. The report addresses corporate governance changes effective July 1, 2020, specifically regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Board Resignation: Donald J. Hayden, Jr. resigned from the Board of Directors, effective July 1, 2020.
- Board Size Reduction: The number of directors was reduced from nine to eight.
- Leadership Appointments: Allan M. Fox was appointed Chairman of the Board, and A.N. "Jerry" Karabelas, Ph.D., was appointed Lead Independent Director, both effective July 1, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to the notification of the director's departure and subsequent board appointments.
Key Facts for Investor Verification
- Verify the effective date of Donald J. Hayden, Jr.'s resignation (July 1, 2020).
- Confirm the new composition of the Board of Directors, specifically the roles of Allan M. Fox and A.N. "Jerry" Karabelas, Ph.D.
- Note that this filing does not impact the company's financial status or operational outlook as reported in other filings.